B-raf antikoerper, HYPT11 antikoerper, SME antikoerper, Sm-E antikoerper, b-raf antikoerper, sm-e antikoerper, sme antikoerper, SmE antikoerper, snRNP-E antikoerper, AL022645 antikoerper, C76690 antikoerper, zgc:56682 antikoerper, small nuclear ribonucleoprotein polypeptide E antikoerper, small nuclear ribonucleoprotein polypeptide E L homeolog antikoerper, small nuclear ribonucleoprotein E antikoerper, SNRPE antikoerper, snrpe.L antikoerper, Snrpe antikoerper, snrpe antikoerper
Hintergrund
B-raf Antibody: B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways interact with each other to regulate growth and in some cases tumorigenesis. Mutations in B-raf have been associated with several cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung, leading to speculation on the possibility of B-raf as a therapeutic target for treating cancers. Mutations in this gene have also been associated with cardiofaciocutaneous syndrome (CFCS), a disease characterized by heart defects, mental retardation and a distinctive facial appearance.
Molekulargewicht
Predicted: 84
Observed: 99, multiple post-translational modifications, commonly observed at 95-100kDa